Epocrates Inc. (EPOC) is Investigated by Faruqi & Faruqi, LLP for Potential Breaches of Fiduciary Duties

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Epocrates, Inc. (“Epocrates” or the “Company”) (NASDAQ: EPOC) for potential breaches of fiduciary duties in connection with their duty to disclose material information in the Preliminary Proxy (“Proxy”) filed with the Securities and Exchange Commission on January 25, 2013 in relation to the sale of the Company to athenahealth Inc. (NASDAQ: ATHN) in an all-cash deal valued at approximately $293 million. Furthermore, the price per share agreed to in the proposed transaction is also under investigation since Epocrates’ stockholders will receive only $11.75 in cash for each share of Epocrates common stock they own, while according to Yahoo! Finance, at least one financial analyst has set a price target of $13 for Epocrates.